Literature DB >> 2052627

Cell surface actions of adriamycin.

T R Tritton1.   

Abstract

Adriamycin has a vast range of reported actions on the structural and functional properties of cells. This review summarizes the literature on the ability of the drug to modulate the cell surface membrane and attempts to address the question of how such actions could be linked to cytotoxicity. In addition, we consider the use of polymer immobilization of adriamycin to separate intracellular from plasma membrane effects of the drug, and show how this approach has been helpful in interpreting the pharmacology of adriamycin. Finally, a range of biophysical and spectroscopic approaches to defining the molecular details of adriamycin-bilayer interactions is surveyed, and the results used to discuss a model for how this antineoplastic agent binds to membranes.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 2052627     DOI: 10.1016/0163-7258(91)90060-y

Source DB:  PubMed          Journal:  Pharmacol Ther        ISSN: 0163-7258            Impact factor:   12.310


  19 in total

1.  Targeting of multidrug-resistant human ovarian carcinoma cells with anti-P-glycoprotein antibody conjugates.

Authors:  Kirk D Fowers; Jindřich Kopeček
Journal:  Macromol Biosci       Date:  2012-01-25       Impact factor: 4.979

2.  Comparison of the anticancer effect of free and HPMA copolymer-bound adriamycin in human ovarian carcinoma cells.

Authors:  T Minko; P Kopecková; J Kopecek
Journal:  Pharm Res       Date:  1999-07       Impact factor: 4.200

Review 3.  Macromolecular carrier systems for targeted drug delivery: pharmacokinetic considerations on biodistribution.

Authors:  Y Takakura; M Hashida
Journal:  Pharm Res       Date:  1996-06       Impact factor: 4.200

4.  Recovery of pituitary function after treatment with a targeted cytotoxic analog of luteinizing hormone-releasing hormone.

Authors:  M Kovacs; A V Schally; A Nagy; M Koppan; K Groot
Journal:  Proc Natl Acad Sci U S A       Date:  1997-02-18       Impact factor: 11.205

5.  Immunotargeting of liposomes to activated vascular endothelial cells: a strategy for site-selective delivery in the cardiovascular system.

Authors:  D D Spragg; D R Alford; R Greferath; C E Larsen; K D Lee; G C Gurtner; M I Cybulsky; P F Tosi; C Nicolau; M A Gimbrone
Journal:  Proc Natl Acad Sci U S A       Date:  1997-08-05       Impact factor: 11.205

Review 6.  Intraperitoneal chemotherapy for ovarian cancer with peritoneal metastases, systematic review of the literature and focused personal experience.

Authors:  Federico Coccolini; Paola Fugazzola; Giulia Montori; Luca Ansaloni; Massimo Chiarugi
Journal:  J Gastrointest Oncol       Date:  2021-04

7.  Expression of apoptosis-related oncoproteins and modulation of apoptosis by caffeine in human leukemic cells.

Authors:  T Efferth; U Fabry; P Glatte; R Osieka
Journal:  J Cancer Res Clin Oncol       Date:  1995       Impact factor: 4.553

8.  Detection of adriamycin-induced cardiotoxicity in cultured heart cells with technetium 99m-SESTAMIBI.

Authors:  D Piwnica-Worms; M L Chiu; J F Kronauge
Journal:  Cancer Chemother Pharmacol       Date:  1993       Impact factor: 3.333

Review 9.  Effects of exogenous lipids on cancer and cancer chemotherapy. Implications for treatment.

Authors:  C P Burns; B A Wagner
Journal:  Drug Saf       Date:  1993-01       Impact factor: 5.606

10.  Isolation of genetic suppressor elements, inducing resistance to topoisomerase II-interactive cytotoxic drugs, from human topoisomerase II cDNA.

Authors:  A V Gudkov; C R Zelnick; A R Kazarov; R Thimmapaya; D P Suttle; W T Beck; I B Roninson
Journal:  Proc Natl Acad Sci U S A       Date:  1993-04-15       Impact factor: 11.205

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.